Literature DB >> 16103754

Comments on progress, medical care, and the overuse of technology.

Marvin Moser.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16103754      PMCID： PMC8109364          DOI： 10.1111/j.1524-6175.2005.04129.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  4 in total

Review 1.  New approaches to hypertension management: always reasonable but now necessary.

Authors:  Carlos M Ferrario
Journal:  Am J Hypertens       Date:  2005-02       Impact factor: 2.689

2.  Resistant hypertension revisited: a comparison of two university-based cohorts.

Authors:  Jay P Garg; William J Elliott; Amy Folker; Munavvar Izhar; Henry R Black
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

3.  Resistant hypertension: comparing hemodynamic management to specialist care.

Authors:  Sandra J Taler; Stephen C Textor; Jo Ellen Augustine
Journal:  Hypertension       Date:  2002-05       Impact factor: 10.190

4.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272
  4 in total
  3 in total

1.  Medical care and technology.

Authors:  Paul A Macri
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-10       Impact factor: 3.738

2.  Re: Overuse of technology.

Authors:  C Venkata S Ram
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-11       Impact factor: 3.738

3.  Whole-Body Imaging Procedures in Resistant Hypertension: Evaluating for Secondary Causes or to Define End-Organ Damages?

Authors:  Mihály B Tapolyai; Ákos Pethő; Tibor Fülöp
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-10-19       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.